Salim Haffar to Join PCI Pharma Services as Chief Executive Officer

PCI Pharma Services (“PCI” or “the Company”), a full-service provider of
specialist outsourced drug manufacturing, clinical trial services, and
commercial packaging to the global healthcare industry, today announced
that Salim Haffar will join the Company as Chief Executive Officer later
this year. Mr. Haffar, who has resigned as President of AptarGroup’s
Aptar Pharma, effective September 1, 2018, will succeed Bill Mitchell,
who will step out of his role as President and CEO of the Company and
assume the position of Executive Co-Chairman, working closely with Mr.
Haffar on behalf of the Board to effect a seamless leadership transition.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180712005212/en/

(Photo: Business Wire)

“I am incredibly proud of what we have accomplished to date at PCI, and
that is a credit to the entire team of talented employees with whom I
have had the pleasure of working over the past six
years,” said Mr. Mitchell. “During that time, we have grown revenue from
$85 million to $600 million, organically and through acquisitions. The
past year has been one of especially strong performance, as we have
completed two exciting acquisitions and achieved year-over-year growth
of over 13 percent. As we continue to build on our strong
foundation and trajectory of success for the benefit of all our
stakeholders, now is the right time to bring in a new chief executive
who can take the baton and lead the management team in advancing PCI to
the next level. Following a thorough and well planned search, the entire
Board and I are confident that Salim Haffar is the right person for the
job. His extensive experience in the pharmaceutical drug delivery
systems and services space and passion for PCI’s Five Commitments make
him well equipped to build on our track record of growth and success, by
continuing to provide customers with the best-in-class service and
solutions they have come to know and expect.”

“On behalf on the Board, I’d like to thank Bill for his outstanding
service as CEO,” said Franz Humer, Co-Chairman of the Board. “We look
forward to continuing to work with Bill in his new role on the Board,
and are thrilled to welcome Salim as PCI’s new CEO. With an experienced
leader like Salim at the helm, and Bill’s continued strategic advice and
guidance as Executive Co-Chairman, we are prepared to execute a smooth
leadership transition and build on PCI’s strong growth and
customer-focused performance.”

Mr. Haffar joins PCI with over 22 years of experience in the
pharmaceutical industry, and currently serves as President of Aptar
Pharma and a member of AptarGroup’s senior executive committee. Mr.
Haffar oversaw Aptar Pharma’s growth strategy and journey to become a
leading global provider of drug delivery systems across three end
markets – prescription, consumer healthcare, and injectables – offering
a broad portfolio of products and services, partnering with
pharmaceutical customers to deliver medicines across several dosage
forms and therapeutic areas, and operating across North America, Europe,
Asia and Latin America. During his tenure at AptarGroup, Mr. Haffar also
served as President of Aptar Pharma’s prescription division,
Co-President of Valois Group, and President of Valois Pharma. Mr. Haffar
has also served as Senior Vice President, EMEA at Capsugel.

“PCI is the partner of choice for healthcare companies around the globe,
and I am honored and excited by the opportunity to lead this great
organization in its next phase of growth,” said Salim Haffar. “With a
team that includes some of the industry’s most experienced
professionals, PCI is well positioned to continue expanding its
portfolio of innovative service offerings, diverse customer base, and
extensive global supply network. I look forward to working with the
entire PCI family, including Bill and the Board, as we continue to
provide the industry’s leading customer experience, the highest quality
and most flexible and reliable service, and the best solutions to solve
our clients’ difficult drug development problems.”

About Salim Haffar

Mr. Haffar has more than 22 years of experience in the pharmaceutical
industry, and currently serves as President of Aptar Pharma and a member
of AptarGroup’s senior executive committee. Mr. Haffar oversaw Aptar
Pharma’s growth strategy and journey to become a leading global provider
of drug delivery systems across three end markets – prescription,
consumer healthcare, and injectables – offering a broad portfolio of
products and services, partnering with pharmaceutical customers to
deliver medicines across several dosage forms and therapeutic areas, and
operating across North America, Europe, Asia and Latin America.

During his tenure at AptarGroup, Mr. Haffar also served as President of
Aptar Pharma’s prescription division, Co-President of Valois Group, and
President of Valois Pharma. Mr. Haffar has also served as Senior Vice
President, EMEA at Capsugel.

Mr. Haffar holds a bachelor’s degree in chemical engineering from McGill
university in Canada, and has extensive multicultural experience having
lived in Europe, the Middle East, Canada and the United States.

About PCI Pharma Services

The global healthcare industry trusts PCI for the development solutions
that increase their products’ speed to market and opportunities for
commercial success. Only PCI brings the proven experience that comes
with more than 50 successful product launches a year and over four
decades in the healthcare business. Leading technology and continued
investment enables us to address global needs throughout the product
life cycle — from preclinical development, clinical investigational
studies, commercialization and ongoing supply. Our clients view us as an
extension of their business and a collaborative partner, with the shared
goal of improving patients’ lives. www.pciservices.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180712005212/en/

Leave a Comment